author-photo

SJ Isakoff

Harvard University

13

Papers

19

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033), a Phase II Randomized Trial of Adjuvant T-DM1 vs. TH in Women With Stage I HER2 Positive Breast Cancer.

2021 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
283MO Ipatasertib (IPAT) + paclitaxel (PAC) for PIK3CA/AKT1/PTEN-altered hormone receptor-positive (HR+) HER2-negative advanced breast cancer (aBC): Primary results from Cohort B of the IPATunity130 randomised phase III trial

2020 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (10)
318PAssociation between PIK3CA mutation status and development of brain metastases in HR+/HER2- metastatic breast cancer

2019 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (3)
Patient Preferences for Use of Archived Biospecimens from Oncology Trials When Adequacy of Informed Consent Is Unclear

2019 Oncologist
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P3-14-02: Upper extremity edema in the at-risk arm among patients receiving PI3K/mTOR/CDK4/6 inhibitors for metastatic breast cancer

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer

2019 bioRxiv
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-11-01: Safety and efficacy of sacituzumab govitecan (anti-Trop-2-SN-38 antibody-drug conjugate) as ≥3rd-line therapeutic option for treatment-refractory HER2-negative metastatic breast cancer (HER2Neg mBC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (3)
Abstract P4-08-08: Genomic progression, detected by circulating tumor DNA (ctDNA) sequencing, as an early predictor of disease progression in metastatic breast cancer (MBC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P2-08-19: Exploratory biomarker analyses of FAIRLANE, a double-blind placebo (PBO)-controlled randomized phase II trial of neoadjuvant ipatasertib (IPAT) + paclitaxel (PAC) for early triple-negative breast cancer (TNBC)

2019 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)